• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7

Purity

≥97%

Formula

C26H46N2O

Formula Wt.

402.66

IUPAC Name

C26H46N2O

Synonym

Bebuxine, Cyclovirobuxine

Melting Point

219-224°C

Appearance

White crystal

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF

Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • Z5653

    Zonisamide

    Sulfonamide; carbonic anhydrase inhibitor, volt...

    ≥96%
  • M0173

    Mastoparan X

    Antimicrobial peptide found in bee and wasp ven...

    ≥95%
  • V7200

    VS-5584

    PI3K inhibitor.

    ≥98%
  • P1753

    Penicillamine

    Penicillin derivative, chelating agent; carboxy...

    ≥97%
  • T7035

    Triptolide

    Diterpenoid epoxide found in Tripterygium.

    ≥98%
  • M4455

    MLN-2238

    Proteasome inhibitor, miR33b modulator.

    ≥95%
  • E6396

    EPZ005687

    EZH2 HMT inhibitor.

    ≥99%
  • C4502

    Clarithromycin

    Macrolide; protein translation inhibitor.

    ≥95%
  • T2970

    Thrombin Receptor Agonist Peptide

    Peptide; PAR1 agonist.

    ≥95%
  • P4492

    PLX4720

    V600E B-Raf inhibitor.

    ≥98%
  • H1862

    Heptaplatin

    Pt-based DNA cross-linker.

    ≥98%
  • W4096

    WKYMVM-NH2

    Synthetic peptide; FPRL1 agonist.

    ≥95%
  • O7332

    OSI-027

    mTOR inhibitor.

    ≥99%
  • A8644

    AVL-292

    BTK inhibitor.

    ≥98%
  • G4480

    Glucagon, human

    Endogenous peptide hormone, counteracts insulin...

    ≥95%
  • S7717

    Sterigmatocystin

    Mycotoxin produced by Aspergillus; carcinogen.<...

    ≥98%
  • C3262

    Ciprofloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • S5753

    Somatostatin-28 (1-14)

    Endogenous neuropeptide hormone; somatostatin a...

    ≥95%
  • V5886

    Voriconazole

    Triazole; 14α demethylase inhibitor.

    ≥98%
  • O4917

    Omeprazole

    H+/K+ ATPase inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only